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Antihistamines are a widely used group of medicines. As well as being prescribed, they are available 
over the counter in many countries. A recent study from France highlighted that each year almost 
one in three children will receive an antihistamine and that in children aged between two and five 
years, almost one in two children will receive an antihistamine [1]. The paper by Vries and Hunsel 
from the Netherlands highlights reported suspected adverse drug reactions (ADRs) to first and 
second generation systemic antihistamines[2].  
Skin eruptions and ADRs involving the central nervous system (headache, somnolence, aggression, 
agitation, hyperactivity and seizures) were the most commonly reported ADRs to second generation 
antihistamines. These ADRs are also the ADRs most frequently associated with first generation 
antihistamines. Second generation antihistamines are thought to be associated with fewer side 
effects. Their findings do not suggest that we should stop using antihistamines in children. They do, 
however, highlight that medicines we consider to be safe do have side effects.  
We know that many side effects are not recognised as such by health professionals. As 
antihistamines are used for the treatment of allergic reactions, one needs to be aware that skin 
eruptions are the most commonly reported ADRs to antihistamines. The mechanism of the skin 
eruptions due to antihistamines is unknown. The fact that it occurs with a variety of antihistamines 
suggests that it is a risk with all antihistamines. If therefore any child  receiving an antihistamine 
develops a fixed skin eruption, one needs to consider the possibility that the drug prescribed is 
responsible. 
 
How common are ADRs?  
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The majority of ADRs are not reported. Additionally, many ADRs are not recognised. It is therefore 
difficult to accurately state how common ADRs in children are. We know that one in ten children in 
hospital will experience ADRs [3]. The prevalence of ADRs in the community, however, is uncertain. 
We know that from a regional study in Cuba that at least one in 500 children will experience an ADR 
each year [3]. This figure however is likely to be an underestimate.  Certain medicines are more likely 
to be associated with ADRs. Cytotoxic agents and antiepileptic drugs are commonly associated with 
ADRs. It is important to recognise however that widely used medicines that we consider safe may 
also be associated with ADRs. The risk benefit for each medicine needs to be carefully considered. 
 
Pharmaceutical company sponsored studies    
Second generation systemic antihistamines are marketed as being safer than first generation 
antihistamines. It was of interest that the pharmaceutical company studies of second generation 
antihistamines did not describe the ADRs documented by Vries and Hunsel. One of the studies 
actually reported convulsions in four children receiving levocetirizine.[4] However, the authors 
considered that the drug was not responsible. The bias associated with pharmaceutical company 
studies is well recognised in adults . This bias has been documented mainly in relation to 
effectiveness. [5]. It is also a problem in relation to toxicity.  We are uncertain whether paediatric 
health professionals are aware of this bias to the same extent.  
 
Looking for ADRs 
Randomised controlled trials are rightly considered to be the best way of determining whether a 
drug is effective or not. They are not however the best way to evaluate drug toxicity. [3] Most 
clinical trials are not sufficiently powered to detect ADRs. Additionally, ADRs are usually poorly 
reported. Prospective cohort studies and national spontaneous reporting schemes for ADRs are 
more effective methods for detecting uncommon ADRs [3]. Health professionals have a 
responsibility to report suspected ADRs to the regulatory agencies. 
 All drugs may result in ADRs 
 Reporting new and serious suspected ADRs is essential to improve pharmacotherapy 
 Stopping a medication may be as important as starting one 
 
Using medicines rationally 
One needs to recognise that all medicines may have ADRs. Additionally, one also needs to be aware 
that many medicines that are prescribed are not actually needed. There is growing recognition in 
elderly patients that many long term medications are not required. There are numerous tools that 
have been developed to assess whether medicines prescribed to the elderly are appropriate or not. 
Within paediatrics, only one such tool has been developed - the POPI [6]. This is an important area of 
research that has been neglected in paediatrics. The rational use of medicines is recognised as being 
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a major problem in low income countries but there is increasing awareness that it is also a problem 
in high income countries. One needs to ask the following questions before prescribing either a new 
medicine or repeating a prescription for an existing treatment. 
 Is a medicine required? 
 Is the medicine to be prescribed likely to be effective, in this age-group for this condition? 
 What are the likely side-effects? 
 What is the risk/benefit to this individual patient? 
 How long is treatment required for? 
Ii is only by asking such questions that one will ensure that patients will receive the optimal 
treatment. 
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